
Please try another search
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company’s Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease; other non-malignant organ diseases through organ transplantation; and various cancers and non-malignant diseases. Cell Source, Inc. is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Yair Reisner | - | 2015 | Chairman of Scientific Advisory Board |
Hermann Einsele | - | - | Member of Scientific Advisory Board |
Steven J. Burakoff | 79 | 2015 | Member of Scientific Advisory Board |
Robert S. Negrin | - | 2015 | Member of Scientific Advisory Board |
Herman Waldmann | 77 | - | Member of Scientific Advisory Board |
George Verstraete | 69 | 2022 | Director |
Darlene D. Soave | 78 | 2021 | Director |
Joseph Rosenthal | - | 2021 | Member of Scientific Advisory Board |
Dennis M. Brown | 73 | 2014 | Executive Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review